Study finds COVID-19 patients who took hydroxychloroquine were less likely to die

Published



Newly released research found that coronavirus patients who took the anti-malarial drug hydroxychloroquine were more likely to survive while being treated in a hospital.

The study, conducted by the Henry Ford Health System in southeast Michigan, measured the mortality rates and treatments of 2,541 patients representing a mix of races, genders, and ages. The research team found that 26% of patients who were not given hydroxychloroquine died compared to 13% of those who were taking the drug. The median age of those studied was 64.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.